RELAPSING REMITTING MULTIPLE SCLEROSIS
Clinical trials for RELAPSING REMITTING MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new RELAPSING REMITTING MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a cancer drug tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis study is testing whether a drug called ixazomib, which is already used for a type of cancer, is safe for people with multiple sclerosis (MS). The drug targets certain immune cells that may drive MS. About 72 adults with relapsing-remitting or progressive MS will take either …
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated May 26, 2026 02:17 UTC
-
Could a cheaper MS drug be just as good?
Disease control Recruiting nowThis study tests whether rituximab, an older and less expensive drug, works as well as ocrelizumab for people with relapsing-remitting multiple sclerosis. About 386 adults aged 18-55 with active MS will receive either drug and be followed for 2 years. The main goal is to see if r…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated May 26, 2026 02:16 UTC
-
Could a stem cell transplant stop MS in its tracks?
Disease control Recruiting nowThis study compares a stem cell transplant (AHSCT) with the best standard treatments for people whose relapsing multiple sclerosis (MS) is not controlled by usual therapies. About 156 adults aged 18 to 55 will be randomly assigned to one of the two approaches and followed for 6 y…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Could a tiny neck implant help repair nerve damage in MS?
Disease control Recruiting nowThis study tests a small device implanted on the vagus nerve in the neck to see if it can safely help repair myelin (the protective coating around nerves) in people with relapsing-remitting multiple sclerosis (RRMS). About 60 adults aged 22-50 will receive the implant; two-thirds…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Phase: NA • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Can a smart app improve MS care? new study seeks answers
Knowledge-focused Recruiting nowThis study is testing a new digital platform designed to help doctors and people with relapsing-remitting multiple sclerosis (MS) better monitor the disease. About 500 participants will use a smartphone app and doctors will use a web-based tool for two years. The goal is to see i…
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 26, 2026 02:12 UTC
-
MS study aims to unlock secrets of B-Cell drug durability
Knowledge-focused Recruiting nowThis study follows 100 people with relapsing-remitting multiple sclerosis who are taking B-cell therapies like ofatumumab or ocrelizumab. Researchers will regularly test blood and use imaging to see how the immune system changes and how that relates to disease activity. The goal …
Matched conditions: RELAPSING REMITTING MULTIPLE SCLEROSIS
Sponsor: Heinrich-Heine University, Duesseldorf • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC